In the current trading session, Navidea Biopharmaceuticals Inc.’s (NAVB) stock is trading at the price of $0.08, a fall of -14.11% over last night’s close. So, the stock is trading at a price that is -87.45% less than its 52-week high of $0.65 and 14.77% better than its 52-week low of $0.07. Based on the past 30-day period, the stock price is -37.06% below the high and +7.74% above the low.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
The 200-day Simple moving average is often placed more emphasis on by traders because of daily price changes. Investors will use the SMA-200 in different situations in trading activity as a key indicator to determine their support and resistance levels, and at the moment, NAVB’s SMA-200 is $0.2203.
It is also essential to consider NAVB stock ratios like the price-to-sales ratio, which is 117.75 for the last year.
How does Navidea Biopharmaceuticals Inc. (NAVB) stock rate among analysts? Buy, sell, or hold?
The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. Currently, there are 0 brokerage firms that recommend the stock as a No Ratings. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1. Using a scale of 1-5, the current average recommendation is 0.00 in simple terms.
Navidea Biopharmaceuticals Inc. (NAVB): Earnings History
If we examine Navidea Biopharmaceuticals Inc.’s recent earnings history, in the last quarter ended on 9/29/2021, it posted adjusted earnings per share of -$0.08, slashing the consensus of -$0.11. In other words, it beat the consensus by $0.03, resulting in a 27.30% surprise. In the 3 months period before the previous quarter which was closed on 9/29/2021, the stock recorded adjusted earnings per share of -$0.08 in contrast with the Outlook of -$0.11. That was a difference of $0.03 and a surprise of 27.30%.
Navidea Biopharmaceuticals Inc. (AMEX: NAVB) Ownership Details
I will give a breakdown of the key shareholders in Navidea Biopharmaceuticals Inc. (NAVB). Recent figures show that the company’s insiders hold 35.43% of shares. A total of 29 institutional investors hold shares in the company, making 1.59% of its stock and 2.46% of its float.
Jun 29, 2023, it was reported that the Company’s largest institutional holder is Allred Capital Management, LLC holding total of 0.29 million shares that make 0.84% of the company’s total number of shares and are currently priced at 27033.0.
The securities firm Vanguard Group Inc holds 0.29 million shares of NAVB, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 0.82%, and the holding percentage of shares is valued at 74525.0.
An overview of Navidea Biopharmaceuticals Inc.’s technicals
In order to learn about trade movements and investor behavior, it is best to analyze the short, medium, and long term technical indicators along with the average volume of a stock. A 20-day average of the stock’s daily volume suggests Navidea Biopharmaceuticals Inc. (NAVB) traded 5,508,279 shares per day, with a moving average of $0.1039 and price change of -0.0127. With the moving average of $0.0987 and a price change of -0.0347, about 9,213,180 shares changed hands on average over the past 50 days. Finally, NAVB’s 100-day average volume is 4,793,046 shares, alongside a moving average of $0.1743 and a price change of -0.2426.
